In a filing, United Therapeutics Corp revealed its CHAIRPERSON & CEO ROTHBLATT MARTINE A unloaded Company’s shares for reported $0.93 million on May 02 ’24. In the deal valued at $258.09 per share,3,600 shares were sold. As a result of this transaction, ROTHBLATT MARTINE A now holds 130 shares worth roughly $34112.0.
Then, ROTHBLATT MARTINE A sold 3,600 shares, generating $900,793 in total proceeds. Upon selling the shares at $250.22, the CHAIRPERSON & CEO now owns 130 shares.
Before that, ROTHBLATT MARTINE A sold 3,600 shares. United Therapeutics Corp shares valued at $847,277 were divested by the CHAIRPERSON & CEO at a price of $235.35 per share. As a result of the transaction, ROTHBLATT MARTINE A now holds 130 shares, worth roughly $34112.0.
Goldman upgraded its United Therapeutics Corp [UTHR] rating to a Neutral from a a Sell in a research note published on February 12, 2024; the price target was increased to $215 from $213. A number of analysts have revised their coverage, including Leerink Partners’s analysts, who began to cover the stock in early February with a ‘”an Outperform”‘ rating. Wells Fargo began covering UTHR with “an Overweight” recommendation on December 08, 2023. UBS started covering the stock on December 06, 2022. It rated UTHR as “a Buy”.
Price Performance Review of UTHR
On Friday, United Therapeutics Corp [NASDAQ:UTHR] saw its stock jump 1.65% to $262.40. Over the last five days, the stock has gained 12.21%. United Therapeutics Corp shares have risen nearly 19.33% since the year began. Nevertheless, the stocks have risen 20.15% over the past one year. While a 52-week high of $261.54 was reached on 05/03/24, a 52-week low of $204.44 was recorded on 02/08/24. SMA at 50 days reached $236.80, while 200 days put it at $230.08. A total of 0.77 million shares were traded, compared to the trading of 0.72 million shares in the previous session.
Levels Of Support And Resistance For UTHR Stock
The 24-hour chart illustrates a support level at 258.05, which if violated will result in even more drops to 253.70. On the upside, there is a resistance level at 264.63. A further resistance level may holdings at 266.86. The Relative Strength Index (RSI) on the 14-day chart is 72.12, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 18.16, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 0.34%. Stochastics %K at 93.46% indicates the stock is a selling.
The most recent change occurred on December 05, 2022 when Goldman began covering the stock and recommended ‘”a Sell”‘ rating along with a $230 price target.
